Building Hidradenitis Suppurativa Treatment Plan: Evaluating Standard of Care Pharmacotherapies
Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.
Proactive Hidradenitis Suppurativa Management: From Watchful Waiting to Active Intervention
Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.
More Research Is Critical to Expand GLP-1 Access for Children: Marry Vuong, PharmD, BCPPS
As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.
Overcoming Challenges in CGM Use Through Education: Marry Vuong, PharmD, BCPPS
Proper placement, device understanding, and ongoing support are key to helping children and adolescents with diabetes benefit from continuous glucose monitors (CGMs), explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.
Health Equity in Hidradenitis Suppurativa: Addressing Care Disparities
Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.
The Pharmacist Advantage: Bridging Gaps in Hidradenitis Suppurativa Care
Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.
Hidden in Plain Sight: Strategies to Improve Early Identification of Hidradenitis Suppurativa
Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for provider education, clinical decision support, and multidisciplinary collaboration to promote earlier recognition and more effective, coordinated care.
Recognizing Hidradenitis Suppurativa: From First Signs to an Accurate Diagnosis
Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered approaches to address the physical, emotional, and social burden of the disease.